EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura und 9 weitere

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05893-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Koshiro Fukuda und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, ErbB Receptors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate circulating tumor DNA (ctDNA) RAS mutant (MT) incidence before salvage-line treatment and the clinicopathological features and molecular biological factors associated with the efficacy of anti-epithelial growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for tissue RAS / BRAF wild type (WT) metastatic colorectal cancer (mCRC).

Methods

This multi-institutional retrospective observational study included 74 patients with mCRC with tissue RAS/BRAF WT refractory to first-line chemotherapy containing anti-EGFR mAb. ctDNA RAS status was assessed using the OncoBEAM™ RAS CRC Kit. We explored the clinicopathological features associated with ctDNA RAS status and the factors related to anti-EGFR mAb rechallenge efficacy in multivariate Cox proportional hazard regression.

Results

The incidence of RAS MT in ctDNA was 40.5% (30/74), which was associated with primary tumor resection ( P = 0.016), liver metastasis ( P < 0.001), and high tumor marker levels ( P < 0.001). Among the 39 patients treated with anti-EGFR mAb rechallenge, those with ctDNA RAS WT showed significantly longer progression-free survival (PFS) than those with ctDNA RAS MT (median 4.1 vs. 2.7 months, hazard ratio [HR] = 0.39, P = 0.045). Patients who responded to first-line anti-EGFR mAb showed significantly longer PFS (HR = 0.21, P = 0.0026) and overall survival (OS) (HR = 0.23, P = 0.026) than those with stable disease.

Conclusions

The incidence of ctDNA RAS MT mCRC was 40.5%, which was associated with liver metastases and high tumor volumes. Anti-EGFR mAb rechallenge may be effective for patients with mCRC who responded to first-line chemotherapy containing anti-EGFR mAb. No patients with RAS MT in ctDNA responded to anti-EGFR mAb rechallenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins B-rafErbB ReceptorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultAged, 80 and overMutationCirculating Tumor DNAAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

RAS/BRAF wild-typeAnti-EGFR monoclonal antibodyCirculating tumor DNARechallengeResponse to first-line anti-EGFR monoclonal antibody

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanErbB ReceptorsEGFR protein, humanCirculating Tumor DNAAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Medical Oncology, Tohoku University Hospital, Miyagi, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Center for Digital Transformation of Healthcare, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Zitieren

APA

Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., Fukuoka, S., Ogura, M., Takahari, D., Chin, K., Shoji, H., Okita, N., Kato, K., Ishizuka, N., Boku, N., …, & Shinozaki, E. (2024). Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05893-1

Vancouver

Fukuda K, Osumi H, Yoshinami Y, Ooki A, Takashima A, Wakatsuki T, et al. Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05893-1

BibTeX
@article{Fukuda2024,
  author = {Fukuda, Koshiro and Osumi, Hiroki and Yoshinami, Yuri and Ooki, Akira and Takashima, Atsuo and Wakatsuki, Takeru and Hirano, Hidekazu and Nakayama, Izuma and Ouchi, Kota and Sawada, Ryoichi and Fukuoka, Shota and Ogura, Mariko and Takahari, Daisuke and Chin, Keisho and Shoji, Hirokazu and Okita, Natsuko and Kato, Ken and Ishizuka, Naoki and Boku, Narikazu and Yamaguchi, Kensei and Shinozaki, Eiji},
  title = {Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05893-1}
}
Kostenlos starten →